Arq. Bras. Oftalmol. 2024; 87 (4): 10.5935/0004-2749.2022-0035
Total: 3263
Pablo Felipe Rodrigues1,2; Bernardo Kaplan Moscovici1; Luciano Lamazales2; Marcela Mara Silva Freitas1; José Álvaro Pereira Gomes1,2; Walton Nosé1; Mauro Silveira Campos1
DOI: 10.5935/0004-2749.2022-0035
1. Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
2. Cornea and Diseases Sector of the Ocular Surface, Instituto Suel Abujamra, São Paulo, SP, Brazil
Corresponding author:
Pablo Felipe Rodrigues
E-mail: [email protected]
Funding: This study received no specific financial support.
Disclosure of potential conflicts of interest: José Álvaro P. Gomes – consultant and speaker: Allergan, Alcon, Genon/Thea Laboratories, Ofta Vision Health, Johnson & Johnson. The other authors have any potential conflicts of interest to disclose.
Approved by the following research ethics committee: Instituto Suel Abujamra (CAAE: 36907320.9.0000.5477).
How to cite this article:
ABO is licensed under a Creative Commons Attribution-NonComercial 4.0 Internacional.
